OBJECTIVES: To present real-world data from a patient registry of multiple sclerosis (MS) patients being treated with cladribine tablets (CT) since its launch in Portugal (PT).

METHODS: Anonymized data was retrieved from a patient support program database of MS patients treated with CT in PT. Data was checked for missing values and descriptive analysis was run for the available information using STATA18. Missing data was censured, with number of samples being mentioned. Information was available from a total of 33 hospitals. Cut-off date for the analysis was May 17^th, 2023.

RESULTS: Overall, 300 patients were included in the analysis, 75,33% were female (23,67% male; 1% unknown). At time of cut-off 24 patients had dropped-out of treatment. Average age of the population (n=277) was 43,54 ± 11,71 years, with a median of 42,50 years, a minimum of 20,6 and a maximum of 77,9 years. The average time on treatment (ToT) with CT for the whole population (n=300) was 2,11 ± 1,24 years, with a median of 1,99 years, minimum of 0,05 and maximum of 4,88 years. For the 24 patients that had dropped-out of treatment ToT was on average 1,87 ± 1,16 years, with a median of 2,00 years. At the time of analysis 22% of patients were undergoing year 1 of treatment, with 29% in year 2, 21% in year 3, 20% in year 4 and 8% in year 5.

CONCLUSIONS: Data observed seems to show that ToT for cladribine tablets seems in line with what has been observed in randomized-controlled trials and in other real-world studies. A total of 8% of patients were still under treatment beyond end of year 4.